Media contact: Investor contact:
• 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*
• 2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals
• Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint
• Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
3 Excludes the net impact of acquisitions and divestitures and translational currency
5 Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
3 Excludes the net impact of acquisitions and divestitures and translational currency
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
3 Excludes the net impact of acquisitions and divestitures and translational currency
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.
MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition- related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and www.factsabouttalc.com .
Regulatory Johnson & Johnson Receives CE Marking for Press Release ACUVUE OASYS MAX Reusable Contact Lenses1 FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune Press Release hemolytic anemia (wAIHA), representing a landmark advancement for patients Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential Press Release first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Press Release Robotic Surgical System Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Press Release Bronchoscopy
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate Data Releases robust 2- year results in the treatment of Press Release adults and adolescents with plaque psoriasis1 Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability Press Release through 2-years, affirming its use as a powerful first line systemic therapy1 Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with Press Release IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement Press Release in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% Press Release of patients in early line relapsed/refractory multiple myeloma New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-hj) to Press Release redene long-term survival expectations in early line relapsed/refractory multiple myeloma CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in Press Release pivotal Phase 3 study RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies Press Release shows low rates of treatment-related events at WCLC 2026 Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall Press Release survival in EGFR exon 20 insertion mutation-positive lung cancer Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, Press Release depression and schizophrenia at Psych Congress 2026 TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and Press Release the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma New Global Survey by Johnson & Johnson Other Finds Most Women Don’t Connect Eye Health Press Release Changes with Menopause1 Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Press Release Chairman Innovative Medicine Effective September Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Press Release Next-Generation Oncology Innovation Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo Press Release CAR-T Programs and Transform Autoimmune Disease Through Immune Reset Johnson & Johnson Announces a Proposed Press Release Resolution of Ovarian Talc Litigation
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website . A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations .
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com .
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results .
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results .
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation . A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com , investor.jnj.com , or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Full text with the tables
Exhibit 99.1
Media contact: Investor contact:
media-relations@its.jnj.com investor-relations@its.jnj.com
For immediate release
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
• 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with
operational growth of 6.0%* and adjusted operational growth of 6.1%*
• 2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time
special charge for the proposed talc litigation resolution, the acquisition of
Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines;
adjusted EPS* of $2.59 also reflects the impact of these M&A deals
• Strong operational performance results in the Company increasing 2026 guidance
with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and
increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint
• Significant innovation including the market authorization of OTTAVA as the
world’s first table-integrated soft tissue robotic system, approval of IMAAVY in
warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT
FASPRO for advanced head and neck cancer
New Brunswick, N.J. (October 13, 2026)
– Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026.
“Johnson & Johnson’s strong third-quarter performance and increased sequential
growth reflect the accelerating momentum of our focused portfolio,” said Joaquin
Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced
breakthroughs that will redefine care for patients, from delivering one of our
most transformative MedTech innovations with OTTAVA to reporting positive Phase
3 results in multiple myeloma. This progress, together with strategic
investments in high-growth areas, gives us clearer line of sight to double-digit
growth by the end of the decade.”
Overall financial results
Q3
($ in
Million… 2026 2025 % Change
except
EPS)
Reported $25,399 $23,993 5.9 %
Sales
Net $210 $5,152 -95.9 %
Earnings
EPS $0.09 $2.12 -95.8 %
(dilute…
Q3
Non-GAA…
($ in
Million… 2026 2025 % Change
except
EPS)
Operati… 6.0 %
Sales1,2
Adjusted
Operati… 6.1 %
Sales1,3
Adjusted
Net $6,339 $6,801 -6.8 %
Earning…
Adjusted
EPS $2.59 $2.80 -7.5 %
(dilute…
Free
Cash ~$15,100 $14,226
Flow5,6
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational
currency
4 Excludes intangible amortization expense and special items
5 Non-GAAP financial measure; defined as cash flow from operating activities,
less additions to property, plant and equipment. Cash flow from operations, the
most directly comparable GAAP financial measure, will be included in subsequent
SEC filings.
6 Third-quarter YTD 2026 is estimated as of October 13, 2026
Note: values may have been rounded
Regional sales results
Q3 %
Ch…
($ Ad…
in 20… 2… Re… Op… Cu… Op…
M…
U… $1… $… 9… % 9… — 9…
I… 1… 10… 1… 1… -… 1…
W… $2… $… 5… % 6… -… 6…
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational
currency
Note: values may have been rounded
Segment sales results
Q3 %
Ch…
($ Ad…
in 20… 2… Re… Op… Cu… Op…
M…
I… $1… $… 7… % 7… -… 8…
M…
M… 8… 8,… 2… 2… 0… 2…
W… $2… $… 5… % 6… -… 6…
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational
currency
Note: values may have been rounded
Third-Quarter 2026 segment commentary:
Operational sales* reflected below excludes the impact of translational
currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures
negatively impacting growth by 10 basis points. Growth was primarily driven by
TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI,
TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA
in Neuroscience. Growth was partially offset by STELARA (an approximate 690
basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well
as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.
MedTech
MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by
electrophysiology products and Shockwave in Cardiovascular, contact lenses in
Vision, as well as trauma in Orthopaedics.
Full-year 2026 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking
basis because the company is unable to predict with reasonable certainty the
ultimate outcome of legal proceedings, unusual gains and losses, acquisition-
related expenses, and purchase accounting fair value adjustments without
unreasonable effort. These items are uncertain, depend on various factors, and
could be material to Johnson & Johnson's results computed in accordance with
GAAP.
($ in
Billions, July 29,
except EPS) October 2026 2026
──────────────────────────────────────────────────────────────────────────────
Adjusted
Operational
Sales1,2 6.4% – 6.8% / 6.2% – 6.8% /
Change vs. 6.6% 6.5%
Prior Year /
Mid-point
Operational $100.5B – $100.3B –
Sales2/ $100.9B $100.9B /
Mid-point /$100.7B $100.6B
Change vs. 6.7% – 7.1% / 6.5% – 7.1% /
Prior Year / 6.9% 6.8%
Mid-point
Estimated
Reported $101.0B – $100.8B –
Sales3/ $101.4B / $101.4B /
Mid-point $101.2B $101.1B
Change vs. 7.2% – 7.6% / 7.0% – 7.6% /
Prior Year / 7.4% 7.3%
Mid-point
Adjusted
Operational $10.95 – $10.86 –
EPS $11.05 / $11.01 /
(Diluted)2,… $11.00 $10.94
Mid-point 1.5% – 2.4% / 0.7% – 2.1% /
Change vs. 2.0% 1.4%
Prior Year /
Mid-point
Adjusted EPS $11.05 – $10.96 –
(Diluted)3,… $11.15 / $11.11 /
Mid-point $11.10 $11.04
Change vs. 2.4% – 3.3% / 1.6% – 3.0% /
Prior Year / 2.9% 2.3%
Mid-point
1 Non-GAAP financial measure; excludes the net impact of acquisitions and
divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15
(Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and
special items
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast .
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson &
Johnson’s other disclosures filed with the Securities and Exchange Commission,
including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and
Annual Reports on Form 10-K. Copies of these filings are available online at
www.sec.gov , www.jnj.com or on request from Johnson & Johnson. The reader is
also encouraged to review all other news releases and information available in
the Investor Relations section of the company’s website at Investor News , as
well as Innovative Medicine Newsroom , MedTech News & Events , and
www.factsabouttalc.com .
Regulatory Johnson & Johnson Receives CE Marking for Press Release
ACUVUE OASYS MAX Reusable Contact Lenses1
FDA approves IMAAVY® (nipocalimab-aahu) as
first-ever treatment for warm autoimmune Press Release
hemolytic anemia (wAIHA), representing a
landmark advancement for patients
Johnson & Johnson's RYBREVANT FASPRO™
(amivantamab and hyaluronidase-lpuj) receives
U.S. FDA Priority Review as potential Press Release
first-in-class EGFR- and MET-targeted
subcutaneous treatment for advanced head and
neck cancer
Johnson & Johnson Receives FDA Market
Authorization in the U.S. for its OTTAVA™ Press Release
Robotic Surgical System
Johnson & Johnson Announces MONARCH™ QUEST 3,
Advancing the Latest in Robotically-Assisted Press Release
Bronchoscopy
New Johnson & Johnson ICOTYDE®
(icotrokinra) long-term data demonstrate
Data Releases robust 2- year results in the treatment of Press Release
adults and adolescents with plaque
psoriasis1
Johnson & Johnson announces new ICOTYDE™
(icotrokinra) data in difficult-to-treat
plaque psoriasis with proven durability Press Release
through 2-years, affirming its use as a
powerful first line systemic therapy1
Johnson & Johnson presents new data
reinforcing sustained disease control and
improved daily function achieved with Press Release
IMAAVY® (nipocalimab-aahu) in generalized
myasthenia gravis (gMG)
Johnson & Johnson announces TREMFYA®
(guselkumab) is the first and only IL-23
inhibitor to show significant improvement Press Release
in spinal pain and stiffness in landmark
axial psoriatic arthritis (PsA) study
Single infusion of CARVYKTI®
(ciltacabtagene autoleucel) delivered
five-year treatment-free remissions in 50% Press Release
of patients in early line
relapsed/refractory multiple myeloma
New model-based analysis further supports
the potential of TECVAYLI®
(teclistamab-cqyv) plus DARZALEX FASPRO®
(daratumumab and hyaluronidase-hj) to Press Release
redene long-term survival expectations in
early line relapsed/refractory multiple
myeloma
CAPLYTA® (lumateperone) shows significant
and rapid improvement in bipolar mania in Press Release
pivotal Phase 3 study
RYBREVANT FASPRO™ (amivantamab and
hyaluronidase-lpuj) plus LAZCLUZE®
(lazertinib) with prophylactic strategies Press Release
shows low rates of treatment-related
events at WCLC 2026
Johnson & Johnson's RYBREVANT®
(amivantamab-vmjw) plus chemotherapy
delivers longest reported median overall Press Release
survival in EGFR exon 20 insertion
mutation-positive lung cancer
Johnson & Johnson spotlights new
neuropsychiatry data across bipolar mania, Press Release
depression and schizophrenia at Psych
Congress 2026
TECVAYLI® + TALVEY® reduced the risk of
disease progression or death by 89% and Press Release
the risk of death by 62% in earlier-line
relapsed/refractory multiple myeloma
New Global Survey by Johnson & Johnson
Other Finds Most Women Don’t Connect Eye Health Press Release
Changes with Menopause1
Johnson & Johnson’s Executive Vice
President Jennifer Taubert to Retire; Tom
Cavanaugh Appointed EVP, Worldwide Press Release
Chairman Innovative Medicine Effective
September
Johnson & Johnson Completes Acquisition of
Firefly Bio, Inc. to Advance Press Release
Next-Generation Oncology Innovation
Johnson & Johnson Announces Collaboration
with Sail Biomedicines to Advance in vivo Press Release
CAR-T Programs and Transform Autoimmune
Disease Through Immune Reset
Johnson & Johnson Announces a Proposed Press Release
Resolution of Ovarian Talc Litigation
1 Subsequent to the quarter
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this
earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the
call for investors and other interested parties may be accessed by visiting the
Johnson & Johnson website . A replay and podcast will be available approximately
two hours after the live webcast in the Investor Relations section of the
company's website at events-and-presentations .
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in
healthcare innovation empowers us to build a world where complex diseases are
prevented, treated, and cured, where treatments are smarter and less invasive,
and solutions are personal. Through our expertise in Innovative Medicine and
MedTech, we are uniquely positioned to innovate across the full spectrum of
healthcare solutions today to deliver the breakthroughs of tomorrow, and
profoundly impact health for humanity. Learn more at www.jnj.com .
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency,
“adjusted operational sales growth” excluding the net impact of acquisitions and
divestitures and translational currency, as well as “adjusted net earnings”,
“adjusted diluted earnings per share” and “adjusted operational diluted earnings
per share” excluding after-tax intangible amortization expense and special
items, are non-GAAP financial measures and should not be considered replacements
for, and should be read together with, the most comparable GAAP financial
measures. Except for guidance measures, reconciliations of these non-GAAP
financial measures to the most directly comparable GAAP financial measures can
be found in the accompanying financial schedules of the earnings release and the
Investor Relations section of the company's website at quarterly results .
Copies of the financial schedules accompanying this earnings release are
available on the company’s website at quarterly results . These schedules
include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson & Johnson, including
adjusted income before tax by segment, an Innovative Medicine pipeline of
selected compounds in late stage development and a copy of today’s earnings call
presentation can also be found in the Investor Relations section of the
company's website at quarterly results .
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995 regarding, among other things:
future operating and financial performance, product development, and market
position and business strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current expectations
of future events. If underlying assumptions prove inaccurate or known or unknown
risks or uncertainties materialize, actual results could vary materially from
the expectations and projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: economic factors, such as interest rate and
currency exchange rate fluctuations or changes to applicable laws and
regulations; competition, including technological advances, new products and
patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory
approvals; uncertainty of commercial success for new and existing products;
challenges to patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans, including restructuring plans;
the impact of business combinations and divestitures; manufacturing difficulties
or delays, internally or within the supply chain; product efficacy or safety
concerns resulting in product recalls or regulatory action; significant adverse
litigation or government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and global health
care reforms; trends toward health care cost containment; changes in behavior
and spending patterns of purchasers of health care products and services;
financial instability of international economies and legal systems and sovereign
risk; increased scrutiny of the health care industry by government agencies; and
the Company's ability to successfully separate the Company's Orthopaedics
business and realize the anticipated benefits from the planned separation . A
further list and descriptions of these risks, uncertainties and other factors
can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K,
including in the sections captioned “Cautionary Note Regarding Forward-Looking
Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent
Quarterly Reports on Form 10-Q and other filings with the Securities and
Exchange Commission. Copies of these filings are available online at www.sec.gov
, www.jnj.com , investor.jnj.com , or on request from Johnson & Johnson. Any
forward-looking statement made in this release speaks only as of the date of
this release. Johnson & Johnson does not undertake to update any forward-looking
statement as a result of new information or future events or developments.